Primary Axillary Hyperhidrosis (PAH) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032
Primary axillary hyperhidrosis (PAH), characterized by excessive sweating in the underarm area, is a distressing condition that profoundly impacts one's social and psychological well-being. It is the most common form of hyperhidrosis and typically begins before age 25. This condition may be inherited as an autosomal dominant genetic disorder with incomplete penetrance. It can manifest in various body parts, including the underarms, palms, groin, chest, and feet. The underlying cause of primary hyperhidrosis is the hyperactivity of the hypothalamic thermoregulatory center, which controls the eccrine sweat glands in the brain. This overactivity is transmitted to the eccrine sweat glands through the sympathetic nervous system. Several treatment modalities are available for PAH, such as using antiperspirants, systemic anticholinergic medications, laser procedures, and surgical interventions, such as sweat gland removal through excision, liposuction, curettage, and laser surgery. There are FDA-approved Glycopyrronium tosylate (GT). 2.4% of cloth is approved for patients nine and older. In contrast, OnabotulinumtoxinA is approved for severe cases of primary axillary hyperhidrosis. Additionally, BOTOX injections are approved by the FDA for individuals with axillary hyperhidrosis that is not adequately managed with topical agents.
·
Hyperhidrosis is a condition that affects approximately
3% of the population, with an estimated prevalence of 2.8% in the United
States, equating to around 7.8 million people. Among those with hyperhidrosis,
50.8% report experiencing axillary hyperhidrosis, affecting approximately 1.4%
of the entire U.S. population.
Thelansis’s “Primary Axillary
Hyperhidrosis (PAH) Market Outlook, Epidemiology, Competitive Landscape, and
Market Forecast Report – 2022 To 2032" covers disease overview,
epidemiology, drug utilization, prescription share analysis, competitive
landscape, clinical practice, regulatory landscape, patient share, market
uptake, market forecast, and key market insights under the potential Primary
Axillary Hyperhidrosis (PAH) treatment modalities options for eight major
markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights
of Primary Axillary Hyperhidrosis (PAH) across 8 MM market from the centre of
Excellence/ Public/ Private hospitals participated in the study. Insights
around current treatment landscape, epidemiology, clinical characteristics,
future treatment paradigm, and Unmet needs.
Primary Axillary Hyperhidrosis (PAH) Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment